US EditionPublished • loading... • Updated
Russian-Cuban Alliance Promotes Study of Amylovis-201 Compound to Treat Alzheimer’s Disease
Summary by Cubadebate
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The Pharmasyntez Group, leader in the Russian pharmaceutical market, and the Center of Neurosciences of Cuba, belonging to BioCubaFarma, announce the launch of a joint project to develop a new drug for the treatment of Alzheimer’s disease. The post Russian-Cuban Alliance promotes study of the compound Amylovis-201 to treat Alzheimer’s disease first appeared on Cubadebate.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
